JE
JEH.F genOway Société anonyme
- Market cap
- EUR 22.8M
- P/E
- -
- P/B
- 0.99x
- ROE
- 3.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is JEH.F undervalued?
Graham numberThe Graham number of genOway Société anonyme cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
genOway Société anonyme fundamental analysis
No fundamental analysis for genOway Société anonyme yet.
genOway Société anonyme stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About genOway Société anonyme
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick K…
Full company profilegenOway Société anonyme financial statements
genOway Société anonyme annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 9.08M | 9.86M | 10.8M | 9.46M | 11.0M | 14.0M | 17.1M | 20.0M | 22.1M | 21.0M |
| Gross Profit | 3.79M | 4.04M | 4.92M | 3.92M | 5.02M | 12.2M | 8.68M | 10.5M | 10.7M | 10.2M |
| Operating Income | -1.96M | -2.20M | -2.60M | -4.41M | -3.82M | -545K | 586K | 156K | 1.40M | 669K |
| EBITDA | - | 2.71M | 1.83M | 454K | 773K | 1.58M | 3.49M | 6.35M | 5.38M | 4.96M |
| Net Income | 582K | 1.93M | 572K | -1.04M | -687K | -323K | 778K | 1.57M | 1.83M | 928K |
| EPS | - | 0.32 | 0.10 | -0.18 | - | -0.04 | 0.10 | 0.19 | 0.20 | 0.08 |
| Balance Sheet | ||||||||||
| Total Assets | 11.7M | 17.2M | 19.7M | 19.2M | 27.6M | 32.7M | 32.9M | 31.8M | 31.8M | 45.4M |
| Total Liabilities | 6.44M | 9.98M | 11.8M | 12.3M | 18.6M | 17.9M | 16.8M | 14.5M | 13.2M | 20.4M |
| Shareholders' Equity | 5.26M | 7.19M | 7.89M | 6.84M | 9.00M | 14.7M | 16.2M | 17.4M | 18.6M | 25.0M |
| Cash & Short-term Investments | 2.64M | 3.95M | 3.05M | 1.09M | 2.72M | 5.61M | 4.88M | 4.26M | 4.95M | 549K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -902K | -164K | -164K | -164K | -164K | - | 2.36M | 3.06M | 5.38M | -1.43M |
| Capital Expenditure | 255K | 2.70M | 2.70M | 2.70M | 2.70M | 0.00 | 1.92M | 1.78M | 2.39M | 10.9M |
| Free Cash Flow | - | - | - | - | - | - | 439K | 1.28M | 2.99M | -12.4M |
| Ratios | ||||||||||
| ROE | 11.1% | 26.9% | 7.2% | -15.1% | -7.6% | -2.2% | 4.8% | 9.0% | 9.9% | 3.7% |
| ROA | 5.0% | 11.2% | 2.9% | -5.4% | -2.5% | -1.0% | 2.4% | 4.9% | 5.8% | 2.0% |
| Net Profit Margin | 6.4% | 19.6% | 5.3% | -11.0% | -6.2% | -2.3% | 4.6% | 7.8% | 8.3% | 4.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
genOway Société anonyme dividends
genOway Société anonyme has not paid dividends in the last 10 fiscal years.
Who owns genOway Société anonyme
- Insiders 31.39%
- Institutions 13.81%
- Public & others 54.80%
- Shares outstanding 12.3M
genOway Société anonyme company profile
- Company name
- genOway Société anonyme
- Ticker
- JEH.F
- ISIN
- FR0004053510
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Technopark 2, Lyon, France, 69007
- Phone
- 33 4 37 65 41 00
- Website
- genoway.com
About genOway Société anonyme
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.
genOway Société anonyme management
1- Dr. Alexandre FraichardFounder, GM & Director